Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | FGFR2 |
Variant | N549D |
Impact List | missense |
Protein Effect | gain of function - predicted |
Gene Variant Descriptions | FGFR2 N549D lies within the protein kinase domain of the Fgfr2 protein (UniProt.org). N549D results in proliferation similar to wild-type Fgfr2 in a competition assay but increased transformation activity in cultured cells (PMID: 34272467) and has been associated with resistance to Fgfr inhibitors in the context of an FGFR2 fusion in culture (PMID: 28034880), and therefore, is predicted to lead to a gain of Fgfr2 protein function. |
Associated Drug Resistance | Y |
Category Variants Paths |
FGFR2 mutant FGFR2 act mut FGFR2 N549D |
Transcript | NM_000141.5 |
gDNA | chr10:g.121498522T>C |
cDNA | c.1645A>G |
Protein | p.N549D |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
NM_001144915.2 | chr10:g.121488065T>C | c.1645A>G | p.N549D | RefSeq | GRCh38/hg38 |
NM_001144919.1 | chr10:g.121488068T>C | c.1645A>G | p.N549D | RefSeq | GRCh38/hg38 |
NM_001144919 | chr10:g.121488068T>C | c.1645A>G | p.N549D | RefSeq | GRCh38/hg38 |
NM_000141.5 | chr10:g.121498522T>C | c.1645A>G | p.N549D | RefSeq | GRCh38/hg38 |
NM_023029.2 | chr10:g.121488065T>C | c.1645A>G | p.N549D | RefSeq | GRCh38/hg38 |
NM_000141.4 | chr10:g.121498522T>C | c.1645A>G | p.N549D | RefSeq | GRCh38/hg38 |
NM_023029.2 | chr10:g.121488065T>C | c.1645A>G | p.N549D | RefSeq | GRCh38/hg38 |
NM_001144915 | chr10:g.121488065T>C | c.1645A>G | p.N549D | RefSeq | GRCh38/hg38 |
NM_001144915.1 | chr10:g.121488065T>C | c.1645A>G | p.N549D | RefSeq | GRCh38/hg38 |
NM_000141 | chr10:g.121498522T>C | c.1645A>G | p.N549D | RefSeq | GRCh38/hg38 |
NM_023029 | chr10:g.121488065T>C | c.1645A>G | p.N549D | RefSeq | GRCh38/hg38 |
NM_001144919.2 | chr10:g.121488068T>C | c.1645A>G | p.N549D | RefSeq | GRCh38/hg38 |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
FGFR2 C382R FGFR2 N549D FGFR2 N549H FGFR2 N549K FGFR2 V564L | cholangiocarcinoma | predicted - resistant | Pemigatinib | Case Reports/Case Series | Actionable | In a Phase II trial (FIGHT-207), FGFR2 N549K, FGFR2 V564L, FGFR2 N549D, and FGFR2 N549H were identified in the post-progression circulating tumor DNA of a patient with cholangiocarcinoma harboring FGFR2 C382R who previously responded to Pemazyre (pemigatinib) treatment (PMID: 38710951; NCT03822117). | 38710951 |
FGFR2 C382R FGFR2 N549D | intrahepatic cholangiocarcinoma | predicted - resistant | Erdafitinib | Case Reports/Case Series | Actionable | In a clinical case study, FGFR2 N550D (reported as N549D) was identified in the post-progression tissue biopsy of a patient with intrahepatic cholangiocarcinoma harboring FGFR2 C382R (reported as C383R) who previously responded to treatment with Balversa (erdafitinib) (PMID: 39226398). | 39226398 |
FGFR2 C382R FGFR2 N549D | intrahepatic cholangiocarcinoma | conflicting | Futibatinib | Case Reports/Case Series | Actionable | In a clinical case study, a patient with intrahepatic cholangiocarcinoma harboring FGFR2 C382R (reported as C383R) and FGFR2 N549D (reported as N550D) experienced progressive disease on treatment with Lytgobi (futibatinib), however, treatment in the patient-derived xenograft (PDX) model resulted in tumor growth inhibition (PMID: 39226398). | 39226398 |